Paola Santana Sánchez

Ms. Paola Santana Sánchez

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
PSPaola Santana Sánchez
Paola Santana Sánchez
Astrid Asminda Ramírez PérezAstrid Asminda Ramírez Pérez
Astrid Asminda Ramírez Pérez
PAPaolo Alberti-Minutti
Paolo Alberti-Minutti
JMJulian Argenis Gajon Martinez
Julian Argenis Gajon Martinez
LBLaura Bonifaz
Laura Bonifaz
ACADRIANA CHAVEZ
ADRIANA CHAVEZ
Objectives: Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder characterized by persistent inflammation. Reliable biomarkers for predicting disease reactivation are lacking. This study aimed to investigate serum cytokines and cytotoxic molecules in both the inactive (iSLE) and active (aSLE) phases to identify potential predictors of disease activity. Methods: Fifty-five SLE patients were classified as having iSLE (n = 36) or aSLE (n = 19) on the basis of clinical parameters and the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K). Serum levels of cytokines, cytotoxic molecules, and CD8+ cells were analyzed through flow cytometry and principal component analysis (PCA). Additionally, seventeen healthy donors (HDs) served as a control group. Results: Serum perforin (median: 2219 pg/mL; p = 0.0020) and granulysin (median: 1347 pg/mL; p = 0.010) levels were significantly higher in patients with aSLE than in patients with iSLE. In contrast, sFas levels were elevated in both SLE groups compared with those in the HD group. Moreover, increased perforin and granulysin levels were correlated with increased SLEDAI-2K scores, and the proportion of cytotoxic cells (CD8+granzyme-B+perforin+ cells) was correlated with disease activity. Conclusions: The increased levels of cytotoxic molecules and the high CD8+ cell proportions suggest that integrating these parameters with traditional biomarkers could enhance disease monitoring and management.

4 January 2025 in Cells
Verified
Journal Article
Open access
PDF file
Aldo Ferreira-HermosilloAldo Ferreira-Hermosillo
Aldo Ferreira-Hermosillo
PSPaola Santana Sánchez
Paola Santana Sánchez
RVRicardo Vaquero-García
Ricardo Vaquero-García
Manuel Ramón García-SáenzManuel Ramón García-Sáenz
Manuel Ramón García-Sáenz
ACAngelica Castro-Ríos
Angelica Castro-Ríos
MHMaria Victoria Legorreta Haquet
Maria Victoria Legorreta Haquet
Type 1 diabetes (T1D) is a complex disease driven by the immune system attacking the insulin-producing beta cells in the pancreas. Understanding the role of different T cell subpopulations in the development and progression of T1D is crucial. By employing flow cytometry to compare the characteristics of T cells, we can pinpoint potential indicators of treatment response or therapeutic inefficacy. Our study reveals elevated prolactin (PRL) levels in T1D patients, along with a decreased production of key cytokines. Additionally, PD1 appears to play a significant role in T1D. Notably, PRL levels correlate with an earlier disease onset and a specific T cell phenotype, hinting at the potential influence of PRL. These findings highlight the need for further research to identify promising cellular targets for more effective and tailored therapies.

2 August 2025 in Cells
Verified
Journal Article
Open access
PDF file
Angel Giovanni Arietta GarcíaAngel Giovanni Arietta García
Angel Giovanni Arietta García
Fernando CalzadaFernando Calzada
Fernando Calzada
AFAntonio Franco-Vadillo
Antonio Franco-Vadillo
IBIrais Barrientos-Buendía
Irais Barrientos-Buendía
FAFrancisco Alarcon Aguilar
Francisco Alarcon Aguilar
Rosa María Ordoñez-RazoRosa María Ordoñez-Razo
Rosa María Ordoñez-Razo
Breast cancer (BC) is the most common type of cancer in women worldwide. Hexokinase II (HKII) overexpression is associated with the proliferation and survival of tumor cells, as it inhibits apoptosis. Incomptine A (IA) is cytotoxic to breast cancer cells, likely due to a decrease in the expression of HKII. This study evaluated the antitumor activity of IA in an in vivo mouse model of BC. A model was generated from 4T1 cells and grouped tumor-bearing animals according to treatment: in IA or doxorubicin (DOXO), or untreated (UT). Comparing the body weight and tumor size between groups, tumors were analyzed using histopathological, Western blot, flow cytometry, and mitochondrial activity assays. Tumors IA-treated showed a reduction in size, weight, and number of tumor cells; the expression of HKII and Bcl-2 decreased, while that of Caspase-3 increased. IA treatment increased apoptosis and reduced mitochondrial activity in tumor cells. This data showed that IA has an impact on tumor cells by reducing tumor volume and size, increasing cell apoptosis, and decreasing mitochondrial activity, all of which could be attributed to reduced HKII expression. Therefore, IA may be a promising compound that requires further studies to elucidate its mechanism of action and analyze its possible future use in BC.